Quantitative analysis of protein and gene expression in salivary glands of Sjogren's-like disease NOD mice treated by bone marrow soup. by Misuno, Kaori et al.
UCLA
UCLA Previously Published Works
Title
Quantitative analysis of protein and gene expression in salivary glands of Sjogren's-like 
disease NOD mice treated by bone marrow soup.
Permalink
https://escholarship.org/uc/item/9wx7s0td
Journal
PloS one, 9(1)
ISSN
1932-6203
Authors
Misuno, Kaori
Tran, Simon D
Khalili, Saeed
et al.
Publication Date
2014-01-29
DOI
10.1371/journal.pone.0087158
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Quantitative Analysis of Protein and Gene Expression in
Salivary Glands of Sjogren’s-Like Disease NOD Mice
Treated by Bone Marrow Soup
Kaori Misuno1, Simon D. Tran2*., Saeed Khalili2, Junwei Huang1, Younan Liu2, Shen Hu1*.
1 School of Dentistry, University of California Los Angeles, Los Angeles, California, United States of America, 2Craniofacial Tissue Engineering and Stem Cells Laboratory,
Faculty of Dentistry, McGill University, Montreal, Quebec, Canada
Abstract
Background: Bone marrow cell extract (termed as BM Soup) has been demonstrated to repair irradiated salivary glands
(SGs) and restore saliva secretion in our previous study. In the present study, we aim to investigate if the function of
damaged SGs in non-obese diabetic (NOD) mice can be restored by BM Soup treatment and the molecular alterations
associated with the treatment.
Methods: Whole BM cells were lysed and soluble intracellular contents (‘‘BM Soup’’) were injected I.V. into NOD mice.
Tandem mass tagging with 2-D liquid chromatography-mass spectrometry was used to quantify proteins in the
submandibular glands (SMGs) between untreated and BM Soup-treated mice. Quantitative PCR was used to identify genes
with altered expression in the treated mice.
Results BM Soup: restored salivary flow rates to normal levels and significantly reduced the focus scores of SMGs in NOD
mice. More than 1800 proteins in SMG cells were quantified by the proteomic approach. Many SMG proteins involved in
inflammation and apoptosis were found to be down-regulated whereas those involved in salivary gland biology and
development/regeneration were up-regulated in the BM Soup-treated mice. qPCR analysis also revealed expression changes
of growth factors and cytokines in the SMGs of the treated NOD mice.
Conclusion: BM Soup treatment is effective to restore the function of damaged SGs in NOD mice. Through gene/protein
expression analysis, we have found that BM Soup treatment might effectuate via inhibiting apoptosis, focal adhesion and
inflammation whereas promoting development, regeneration and differentiation of the SG cells in NOD mice. These
findings provide important insights on the potential mechanisms underlying the BM Soup treatment for functional
restoration of damaged SGs in NOD mice. Additional studies are needed to further confirm the identified target genes and
their related signaling pathways that are responsible for the BM Soup treatment.
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Introduction
Sjo¨gren’s syndrome (SS) is a chronic autoimmune disease, with
an estimated prevalence of ,4 million in the US [1,2]. Patients
with SS suffer from dry mouth (xerostomia) and eyes (xeropthal-
mia) caused by lymphocytic infiltration of salivary and lachrymal
glands. SS primarily affects women, with a ratio of 9:1 over the
occurrence in men. The disease is classified as primary SS when it
exists by itself or secondary SS when it is associated with another
autoimmune disease such as rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE) or systemic sclerosis. In addition,
patients with SS have a significant higher risk of developing
lymphoma than both healthy population and patients with other
autoimmune diseases [3]. The most common form is mucosa-
associated lymphoid tissue (MALT) lymphoma that remains
localized in the affected salivary glands.
A typical pathological feature of SS is the presence of
progressive lymphocytic infiltrates in the exocrine glands, such as
salivary and lachrymal glands, where lymphocytes are not
normally found [4]. Histopathological examination of the affected
major salivary glands in patients with SS reveals a benign
lymphoepithelial lesion, which is characterized by lymphocytic
replacement of the salivary epithelium and accompanied by the
formation of epimyoepithelial islands mainly composed of keratin-
containing epithelial cells [5,6]. The predominant cells in the
salivary gland infiltrates are T cells, with a ratio of 3–5:1 between
CD4+ and CD8+ phenotypes. SS is also associated with B cell
hyperactivity as manifested by the production of autoantibodies,
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hypergammaglobulinemia, formation of ectopic lymphoid struc-
tures within the inflamed tissues, and enhanced risk of B cell
lymphoma [7]. B cells constitute approximately 20% of the total
infiltrating population [6]. Various autoantibodies, such as anti-
SS-A (Ro), anti-SS-B (La), anti-a-fodrin, anti-M3 muscarinic
acetylcholine receptor (anti-M3R), anti-histone and anti-transglu-
tamine are detected in serum or saliva fluids of patients with SS
[4,8–10].
The present level of mechanistic understanding of SS etiology
and pathogenesis is inadequate, and accordingly there are no
treatments that modify the evolution of SS in patients [11]. The
efficacy of local treatments such as artificial tears or oral sprays is
limited, whereas molecular-targeted therapies remain at early-
stage clinical trials in SS patients. Recent studies suggest that cell-
based therapies may emerge as a valid treatment approach for SS.
For instance, transplantations with bone marrow-derived cells
(BMDCs), splenic stem cells or salivary gland (adult) stem cells,
have shown promises to restore the function of damaged salivary
glands in animal models with SS-like disease or under irradiation
treatment [12–14]. Transplantation of BMDCs is traditionally
used for hematologic diseases, but there is an increasing interest in
using BMDC treatments for non-hematologic disorders, including
autoimmune diseases such as SS [12,15]. Tran and colleagues
initially observed that BMDCs from healthy male donors can
differentiate into buccal (oral) epithelial cells of female transplant
recipients and, recently, confirmed that a small percentage of Y-
chromosome positive salivary cells (mean of ,1%) are present in
the biopsied salivary glands of five female patients, who received
allogeneic BMDC or peripheral blood stem cell (PBSC) transplants
from their brothers [16,17]. The same research group has devoted
significant efforts to demonstrating allogeneic BMDC transplants
for treating SS in the NOD mice, which is an animal model
displaying infiltrates of lymphocytes and a gradual loss of salivary
function. In a recent study [18], they tested the long-term effects
(52 weeks post-therapy) of complete Freund’s adjuvant (CFA,
immunopotentiator) and MHC class I-matched normal BMDCs
to 7-week old NOD mice prior to SS onset. At week 52 post-
treatment, NOD mice treated with CFA+BMDCs were normo-
glycemic compared to the control group, and had their salivary
glands’ function restored both quantitatively and qualitatively.
Saliva production was significantly higher in BMDC-transplanted
mice when compared to control NOD mice who continued to
have their saliva production deteriorated over time. Similar
strategy using BMDC transplants was also used to functionally
restore irradiated salivary glands in animal models [19–21].
Recently, to test the mechanisms of action behind these
reported successes using BMDCs for restoring salivary gland
function, Tran and colleagues lysed whole BMDCs cells and
injected the soluble intracellular contents (termed as ‘‘Bone Marrow
Soup’’; BM Soup) into mice with irradiation-injured SGs [22]. Their
hypothesis was that if a paracrine effect was at play, BM Soup
would protect salivary cells, increase tissue neovascularization,
salivary function, and regeneration following irradiation damage.
BM Soup was found as an efficient therapeutic agent as injections of
live BMDCs. In addition, use of BM Soup is advantageous as it
contains only the cell by-products and no whole live BMDCs
which carry the risk of differentiating into unwanted/tumorigenic
cell types in SGs.
Proteomic studies of SS have revealed a number of target
proteins that may reflect the disease mechanisms or serve as
diagnostic markers. It has been found that the proteomes of saliva
or salivary gland cells from SS patients display increased
expression of inflammatory proteins and decreased expression of
acinar proteins [23–28]. We have discovered saliva protein and
autoantibody biomarkers for SS using both mass spectrometry and
protein microarray based proteomics. These markers have been
successfully validated in independent patient cohorts, demonstrat-
ing their high sensitivity and specificity for the disease detection
[9,29,30]. By using gene co-expression network analysis of
expression microarray data and then correlation with proteomic
analysis, we also revealed gene networks and signaling pathways
that are associated with SS and associated MALT lymphoma [31].
The purpose of this study is to determine the molecular changes
underlying the BM Soup treatment for restoration of damaged
salivary glands in NOD mice. We report here a quantitative
analysis of protein and gene expression changes in submandibular
gland (SMG) tissue cells from untreated and BM Soup-treated
NOD mice. Using proteomics and quantitative PCR, important
target genes associated with BM Soup treatment have been
identified and verified, which reveals potential molecular mech-
anisms underlying the functional restoration of damaged salivary
glands in SS-like disease.
Results
Measurement of Salivary Gland Function of BM Soup
Treated NOD Mice
We assessed the efficacy of BM Soup in repairing SMGs that
were damaged in NOD mice. At week 16, BM Soup-treated mice
had a 35% improvement of their salivary flow rate (SFR) while
untreated mice had a 38% reduction (Fig. 1A, p,0.05). At week
20, the SFR of BM Soup-treated mice was slightly reduced (27%)
whereas the SFR of untreated NOD mice further deteriorates to
40% below the baseline level. These data indicated that BM Soup
treatment was valid in re-establishing saliva secretion. Meanwhile,
the focus score of the SMGs in BM Soup-treated mice was
significantly lower than that of the untreated NOD mice (Fig. 1B,
p,0.05). The average focus scores were 2.34 in the untreated
control group and 0.25 in the BM Soup-treated group, suggesting
that BM Soup treatment suppresses the lymphocytic infiltration in
the SMGs of the NOD mice.
Quantitative Proteomic Analysis of the SMGs of BM Soup-
treated NOD Mice
In total, 1855 SMG tissue proteins were quantified between
untreated and BM Soup-treated NOD mice based on TMT
labeling and 2-D LC-MS/MS (Fig. 2A, Table S1). At least two
unique peptides were confidently matched for each protein and
also labeled with TMT. A representative list of proteins involved in
inflammation, apoptosis or transcriptional regulation is shown in
Table 1. These proteins were down-regulated in the SMG tissue
cells of BM Soup-treated NOD mice when compared to untreated
NOD mice. A second representative list of proteins involved in
transcriptional regulation, stem cell biology or salivary gland
biology is shown in Table 2. These SMG proteins were up-
regulated in the BM Soup-treated NOD mice versus untreated
NOD mice.
Functional Pathway Analysis
DAVID/KEGG pathway analysis was performed on the
differentially expressed proteins to evaluate which pathways were
significantly represented in BM Soup treated SMG tissue cells.
Four pathways were found to be significant (p#0.01) including
calcium signaling pathway, inositol phosphate metabolism, focal
adhesion and extracellular matrix (ECM) - receptor interaction
(Table 3). These four pathways play an important role in the
differentiation and apoptosis of different cell types including stem
cells.
Bone Marrow Cell Treatment for Sjogren’s Disease
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Figure 1. Salivary flow rates (SFRs, Figure 1A) and focus scores (Figure 1B) of the untreated and BM Soup-treated NOD mice (n=6
mice per group). In Figure 1A, the white bars represent untreated NOD groups whereas the black bars represent treated NOD groups. **, p,0.01; *,
p,0.05.
doi:10.1371/journal.pone.0087158.g001
Figure 2. Quantitative proteomic analysis of SMG tissue proteins in untreated and BM SOUP treated NOD mice (n=4 per group)
using tandem mass tagging and 2-D LC-MS/MS. (A) Ratios of 131 to 130 represent the relative levels of proteins between BM SOUP-treated
(TMT-131) and untreated (TMT-130) NOD mice. In total, 1885 proteins were identified with at least two matched, TMT-labeled peptides. (B) The
relative expression levels of vimentin (VIM), parotid secretory component protein (PSP), alpha-amylase (AMY), aquaporin 5 (AQP5), lacrimal androgen-
binding protein (LABP), Sjogren’s syndrome antigen B (SSB), aquaporin 1 (AQP1) and caspase 8 associated protein 2 (CASP8AP2) between untreated
and BM Soup-treated mice.
doi:10.1371/journal.pone.0087158.g002
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qPCR Analysis of Gene Expression in the SMGs of BM
Soup Treated NOD Mice
Four up-regulated proteins in the treated NOD group,
including alpha-amylase (AMY), vimentin (VIM), parotid secreto-
ry protein (PSP) and aquaporin 1 (AQP1), and three down-
regulated proteins in the treated NOD group, including lacrimal
androgen-binding protein (LABP), Sjogren’s syndrome antigen B
(SSB) and caspase 8 associated protein 2 (CASP8AP2), were
further tested at mRNA level with qPCR. As shown in Fig. 3,
qRT-PCR analysis indicated that three out of seven genes (VIM,
LABP and SSB) were significantly altered in treated NOD group
versus untreated NOD group (p,0.05). Although the difference is
not statistically significant presumably due to limited sample size,
the average gene expression levels were increased around 4-fold
for PSP, 7.5-fold for AMY and 4.7-fold for AQP1 in treated NOD
group when compared to untreated NOD mouse group.
BM Soup treatment also altered the expression of growth
factors/cytokines in the SMGs of NOD mice. Growth factors and
cytokines are relatively low abundant, therefore they were not
readily detected with the MS-based proteomic approach. Howev-
er, as shown in Fig. 4, qRT-PCR analysis indicated that
epidermal growth factor (EGF) and nerve growth factor (NGF)
were significantly up-regulated whereas tumor necrosis factor
alpha (TNFa) was significantly down-regulated in the BM Soup-
treated NOD group. Meanwhile, AQP5 (aquaporin 5) and BMP7
(bone morphogenetic protein 7), which is a member of the TGF
superfamily, were also significantly up-regulated in the treated
group. There were slight changes in the gene expression of VEGF
(vascular endothelial growth factor) and transforming growth
factor beta 1 (TGFb1) between the untreated and treated groups
but the differences were not statistically significant.
Discussion
One of the main findings in our study is that BM Soup
treatment effectively improved the SFR of NOD mice. SFR
directly reflects function of the glands and its decrease is one of the
major clinical findings in patients with Sjogren’s syndrome (SS).
Therefore, an improved SFR of the NOD mice indicated that BM
Soup treatment was efficient in restoring salivary gland function.
In addition, BM Soup treatment inhibited the lymphocytic
infiltration of SGs in the NOD mice, as evidenced by significantly
reduced focus scores in the treated NOD mice. Timing in testing
experimental therapies in NOD mice is a critical factor. NOD
mice develop Sjogren’s-like disease (SS-like) in three phases [32].
Phase 1 (from 0 to 8 wks of age) is independent of detectable
autoimmunity. In phase 2 (8–16 wks; onset of disease), the
autoimmunity believed to result from the acinar cell apoptosis
leads to leukocytes infiltrating in the SGs. After 16 wks of age
Table 1. A partial list of down-regulated SMG proteins in BM SOUP-treated NOD mice.
Accession Number Ratio 131/130 # of Peptides Protein Name
IPI00127754.1 0.399 2 Lacrimal androgen-binding protein
IPI00751076.1 0.405 17 Actin, cytoplasmic 2
IPI00120155.1 0.498 3 Interleukin-6 receptor beta chain precursor
IPI00126055.1 0.591 2 EGF-containing fibulin-like extracellular matrix protein 2 precursor
IPI00124675.1 0.622 2 Interferon-induced guanylate-binding protein 1
IPI00116861.4 0.625 2 Protein regulator of cytokinesis 1-like protein (Fragment)
IPI00221718.1 0.631 2 Polypeptide N-acetylgalactosaminyltransferase 12
IPI00473603.1 0.632 3 Sjogren syndrome antigen B
IPI00754562.1 0.644 2 Isoform 1 of Membrane-associated phosphatidylinositol transfer protein 2
IPI00124590.3 0.669 6 CASP8-associated protein 2
IPI00319992.1 0.689 27 78 kDa glucose-regulated protein precursor
IPI00668028.2 0.691 4 nucleoporin 210 kDa-like
IPI00411016.1 0.697 3 Lacrimal androgen-binding protein epsilon
IPI00123639.1 0.699 12 Calreticulin precursor
IPI00352163.3 0.706 2 Fibronectin 1
IPI00163011.2 0.736 4 Thioredoxin domain-containing protein 5 precursor
IPI00652063.2 0.737 3 FAT tumor suppressor homolog 3 isoform 2
IPI00131533.1 0.761 2 Caspase-8 precursor
IPI00114342.1 0.782 2 Hexokinase-2
IPI00129796.2 0.790 2 POU domain, class 3, transcription factor 1
IPI004657896.3 0.795 3 Talin-1
IPI00667941.1 0.800 3 Inositol 1,4,5-trisphosphate 3-kinase B isoform 2
IPI00410989.2 0.804 4 ATP-binding cassette transporter sub-family A member 16
IPI00223699.4 0.811 4 Extracellular matrix protein FRAS1 precursor
IPI00113575.1 0.813 3 Kallikrein 1-related peptidase b16 precursor
IPI00348451.5 0.818 2 Caspase recruitment domain protein 12
IPI00658501.1 0.820 6 Microtubule-associated protein 1 A isoform 5
doi:10.1371/journal.pone.0087158.t001
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(Phase 3), loss of SG secretory function occurs (advanced disease).
Our group has tested BM cell therapy in NOD at different phases
of SS-like disease, such as at 8, 14, and 20 weeks of age [18,33–
35]. In our latest study [35], we injected a combined-therapy
(consisting of immuno- and bone marrow cell-based therapy)
during either the initial phase of SS-like (8-week old NOD), or at
an advanced phase (20-week old NOD). We reported that BM cell
therapy maintained salivary flow rates between 80–100% of pre-
symptomatic levels when given at 8 weeks of age, while when the
therapy was given at an advanced phase of SS-like (20 weeks and
older), salivary flow rates improved, but were at best 50% of pre-
symptomatic levels. Since the goal of this manuscript is to show
proof-of-concept of a new therapy (BM Soup) against SS-like
disease, we provided the therapy at the critical time point of 8
weeks of age to NOD to maximize our chances to detect a
significant improvement in saliva flow rate.
At the molecular level, BM Soup treatment altered the protein
expression of a number of genes, particularly those involved in the
proliferation, inflammation, apoptosis as well as tissue repair and
regeneration in the SGs of NOD mice (see summary in Table 4).
Our studies showed that a-amylase was up-regulated at the protein
level in the SMG cells of BM Soup-treated NOD mice when
compared to untreated NOD mice. Although the difference in the
gene expression of a-amylase was not statistically significant due to
limited sample size in each studied groups, the mRNA level of a-
amylase was increased at 7.5-fold in treated NOD group when
compared to untreated NOD group. Baldini et al. found that there
was a significant decrease of a-amylase in SS patients compared to
healthy and non-SS sicca syndrome subjects [36]. Previous report
also revealed that the decrease of amylase in SS is due to acinar
parenchymal damage [28], and the expression of acinar-specific
markers such as a-amylase and cystatin could help differentiate
ductal cells into acinar cells [37–39]. The up-regulation of a-
amylase in BM Soup-treated NOD mice suggests that the protein
expression of salivary a-amylase in NOD mice was restored by
BM Soup treatment. The elevated levels of salivary a-amylase may
help differentiate ductal cells to acinar parenchymal cells.
We also found that aquaporin 1 (AQP1) protein was up-
regulated in the SMG cells of the NOD mice by the BM Soup
treatment. Although the difference in the gene expression of
AQP1 was not statistically significant due to limited sample size in
the studied groups, the average level of AQP1 mRNA was
Table 2. A partial list of up-regulated SMG proteins in BM SOUP-treated NOD mice.
Accession Number Ratio 131/130 # of Peptides Protein Name
IPI00121550.1 1.202 9 Sodium/potassium-transporting ATPase subunit beta-1
IPI00128296.1 1.204 6 Creatine kinase, ubiquitous mitochondrial precursor
IPI00122958.1 1.205 2 Induced myeloid leukemia cell differentiation protein Mcl-1 homolog
IPI00663736.1 1.205 3 Similar to Ras GTPase-activating protein SynGAP
IPI00466650.1 1.209 3 Isoform 2 of Calcium/calmodulin-dependent 39,59-cyclic nucleotide
phosphodiesterase 1C
IPI00123183.2 1.234 2 Aquaporin-1
IPI00129264.1 1.237 2 Vinexin
IPI00114982.1 1.247 2 Signal transducer and activator of transcription 5B (STAT5B)
IPI00274030.3 1.247 4 splicing factor, arginine/serine-rich 8 isoform 1
IPI00410905.1 1.250 2 Isoform 5 of Calcium-activated potassium channel alpha subunit 1
IPI00130116.1 1.303 2 Transient receptor potential cation channel subfamily M member 2
IPI00222042.1 1.328 3 Sorting nexin-14
IPI00622013.2 1.334 2 RAS-like family 11 member B
IPI00130920.1 1.363 2 Microtubule-associated protein 1B
IPI00400329.2 1.385 2 NF-kappa-B-repressing factor
IPI00380983.3 1.387 2 MRS2-like, magnesium homeostasis factor
IPI00315893.1 1.537 10 Alpha-amylase 1 precursor
IPI00453692.3 1.585 3 Nestin
IPI00227299.5 1.610 6 Vimentin
IPI00223523.1 1.980 3 Autoimmune regulator, isoform 3b
IPI00626585.2 2.301 2 Calcium-dependent secretion activator 2, isoform 5
IPI00131763.1 2.445 7 Parotid secretory protein precursor
IPI00122048.2 2.928 14 Sodium/potassium-transporting ATPase alpha-3 chain, Aquaporin pathway related
doi:10.1371/journal.pone.0087158.t002
Table 3. The KEGG pathways associated with BM Soup
treatment as revealed by the DAVID analysis.
Functional pathway Protein count P value
Calcium signaling pathway 12 0.002
Inositol phosphate metabolism 6 0.004
Focal adhesion 11 0.006
ECM-receptor interaction 7 0.006
doi:10.1371/journal.pone.0087158.t003
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increased at 4.7-fold in treated NOD group when compared to
untreated NOD group. Aquaporins are water channel proteins
that play an important functional role in salivary secretion. AQP1,
AQP3, AQP4 and AQP5 are expressed and localized in major
human salivary glands (parotid, SMG, sublingual) as well as labial
glands [40,41]. In fact, AQP1 is expressed in salivary gland
myoepithelial cells. The presence of AQP1 in myoepithelial cells
plays an important role in saliva secretion, since myoepithelial cells
embrace acinar cells; the aquaporin might ensure the water flow
into the basal aspect of the acinar epithelial cells [42]. In addition,
the expression of AQP1 was significantly down-regulated in the
salivary gland tissue cells of SS patients [43]. Similarly, as
indicated by the qPCR analysis, the gene expression of AQP5 was
significantly up-regulated in the BM Soup-treated NOD group
versus untreated NOD group (p,0.05, Figure 4). Our results
suggest that the BM Soup treatment elevates the expression of
AQP1 and AQP5 in the SMG cells, which may contribute to the
improved saliva flow rates in NOD mice.
BM Soup treatment also led to the up-regulation of parotid
secretory protein (PSP, .2.4 fold increase) in the NOD mice,
which is a secreted protein involved in binding and clearing
various infectious agents [44,45]. qPCR analysis also indicated a 4-
fold increase of average PSP mRNA expression level in the treated
NOD group although the difference was not statistically signifi-
cant. Previous studies indicated that aberrant synthesis and
processing of PSP in the SMGs of NOD-scid mice correlates to
the time of appearance of lymphocytes in the parental NOD mice.
It also correlates with a loss of acinar cells through time and an
Figure 3. Relative gene expression of VIM, PSP, AMY, AQP1, LABP, SSB, and CASP8AP2 in the SMGs of the BM SOUP-treated NOD
mouse group (n=4) versus the untreated NOD mouse group (n=4). The mRNA levels of VIM, LABP and SSB were found to be significantly
altered in the treated NOD group (*p,0.05). Although the average mRNA levels were increased with 4-fold for PSP, 7.5-fold for AMY and 4.7-fold for
AQP1 in treated NOD group, the differences were not statistically significant, which may be presumably due to limited sample size for each studied
group.
doi:10.1371/journal.pone.0087158.g003
Figure 4. Relative gene expression of TNFa, TGFb1, IGFR, EGF, NGF, VEGF, BMP7 and AQP5 in the SMGs of the BM SOUP-treated
NOD mice (n=4) versus the untreated NOD mice (n=4). The mRNA levels of TNFa, EGF, NGF, BMP7 and AQP5 were significantly altered in the
treated NOD group (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0087158.g004
Bone Marrow Cell Treatment for Sjogren’s Disease
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increase of a ductal cell population [44]. The elevated expression
of PSP protein in BM Soup treated NOD mice may contribute to
the decreased activity of infiltrating lymphocytes in the salivary
glands.
Both vimentin and nestin were up-regulated at protein level in
BM Soup-treated NOD mice versus untreated NOD mice. The
mRNA expression level of vimentin was also significantly up-
regulated in the treated NOD mouse group (p,0.05). Nestin is a
stem cell marker expressed by many types of cells during
development while vimentin is expressed in mesenchymal cells
and involved organogenesis, wound healing and tumor invasion.
In fact, vimentin appears as an important biomarker in epithelial-
mesenchymal transition (EMT) which is responsible for generation
of stem cells during the tissue repair [46]. In a previous study, You
et al. found that vimentin and nestin were both up-regulated
during repair of lacrimal glands in mice. Their results showed that
there was a presence of a heterogeneous population of mesenchy-
mal stem cells (MSCs) based on the expression of nestin and
vimentin in the lacrimal glands [47]. Since MSCs are the major
type of stem cells in bone marrow, our finding suggests that the
factors present in BM Soup induced the expression of nestin and
vimentin, which might stimulate the tissue regeneration and repair
in the SMGs of NOD mice.
Proteomic analysis also revealed the down-regulation of Sjogren
syndrome antigen B (SSB), caspase 8 (CASP8), CASP8-associated
protein 2 (CASP8AP2), and kallikrein-1 related peptidase in BM
Soup-treated NOD mice versus the untreated NOD mice. qPCR
analysis further confirmed that the mRNA level of SSB was
significantly down-regulated in the treated NOD mice. Caspases
play an important role in the initiation and execution of the
apoptosis process. They are synthesized as inactive zygogens that
become activated by cleavage via upstream proteases and, once
activated, lead to cell death via extrinsic or intrinsic pathways [48].
The extrinsic pathway involves the death receptor such as Fas and
is initiated by the TNF-receptor family members, leading to the
cleavage and activation of initiator caspase-8 [48]. Indeed,
increased apoptosis of salivary gland epithelium was observed in
SS patients, with elevated expression of Fas and FasL in glandular
ductal and acinar cells [49]. These results imply that BM Soup
treatment inhibits the expression of caspase-8 and apoptosis of
SMG cells in the NOD mice.
Sjogren’s syndrome antigen B (SSB) is an autoantigen associated
with autoimmune disorders. In fact, serum anti-SSB/La autoan-
tibody serves as a commonly used marker for diagnosis of SS.
Previously we found that salivary anti-SSB/La level was signifi-
cantly higher in primary SS patients compared with systemic lupus
erythematosus (SLE) and healthy control individuals [9]. In the
present study, the BM Soup treatment down-regulated the
expression of SSB autoantigen in the SMG cells, which suggests
a decreased autoimmune activity in the BM Soup-treated NOD
mice. Kallikreins are a group of serine proteases classified into two
categories, plasma kallikreins (blood plasma) and tissue kallikreins
(glandular organs) [50]. Kallikrein cascade play an important role
in the initiation and maintenance of inflammatory responses [51].
In fact, both kallikrein-1 and kallikrein-13 were found to be up-
regulated in the salivary glands of IQI/Jic mice [52]. Our study
seems to indicate that the BM Soup treatment decreased the
activity of kallikrein 1 in the NOD mice.
The KEGG pathway analysis of proteomic data indicates that
some of the differentially expressed proteins are associated with
calcium signaling, inositol phosphate metabolism and focal
adhesion pathways. Calcium plays an important role in biological
signaling, protein secretion, exocytosis, and muscle contraction
[53,54]. Oscillations in Ca2+, in response to Ca2+ mobilizing
stimuli, are observed in many non-excitable cells, such as
pancreatic acinar cells, oocytes, liver cell, and fibroblast [55].
Calmodulin and calreticulin are calcium binding proteins which
mediate the biological effects of Ca2+ [56]. These proteins were
found to be up-regulated in salivary gland cells of SS patients
which might be due to the interaction with autoantigen La/SSB
[25,26]. The over-expression of calreticulin, in fact, caused a
decrease in the rate of Ca2+ mobilization from the internal stores
Table 4. A list of potential target proteins of action by BM SOUP treatment.
Protein name Current study Previous study References
Inflammation-related
Kallikrein 1- related peptidase Down-regulated in BM SOUP-treated NOD mice Up-regulated in salivary glands of IQI/Jic mice [52]
Calreticulin/Calmodulin Down-regulated in BM SOUP-treated NOD mice Up-regulated in salivary glands of IQI/Jic mice [24,25]
SS biomarker
Sjogrens syndrome antigen B Down-regulated in BM SOUP-treated NOD mice Up-regulated in SS patients [9,63]
Salivary gland biology
a-Amylase Up-regulated in BM SOUP-treated NOD mice Down-regulated in SS patients [36–39]
Aquaporin-1 Up-regulated in BM SOUP-treated NOD mice Down-regulated in SS patients [40,41,43]
Aquaporin-5 Up-regulated in BM SOUP-treated NOD mice Down-regulated in SS patients [40,41,43]
Parotid secretory protein Up-regulated in BM SOUP-treated NOD mice Down-regulated in SS patients [44,45]
Stem cell and development
Nestin Up-regulated in BM SOUP-treated NOD mice Up-regulated in repaired lacrimal glands [47,64]
Vimentin Up-regulated in BM SOUP-treated NOD mice Up-regulated in repaired lacrimal glands [47,64]
Apoptosis
CASP8-associated protein 2 Down-regulated in BM SOUP-treated NOD mice Up-regulated in SS [49,65]
Caspase-8 Down-regulated in BM SOUP-treated NOD mice – –
Caspase recruitment domain
protein 12
Down-regulated in BM SOUP-treated NOD mice – –
doi:10.1371/journal.pone.0087158.t004
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[57]. We found that calreticulin expression in SMG cells was
down-regulated by BM Soup treatment, which may restore the
Ca2+ signaling and flow in the SMG cells of NOD mice.
Meanwhile, we found inositol 1,4,5- trisphosphate 3-kinase B
(IP3K) and membrane-associated phosphatidylinositol transfer
protein 2 were down-regulated in BM Soup-treated NOD mice.
Both proteins are involved in inositol phosphate metabolism.
Inositol 1,4,5-trisphosphate (IP3) is a secondary messenger and
responsible for the regulation of Ca2+ activation/chloride efflux
and also has a role in inositol phosphate metabolism pathway [58].
The phosphatases and kinases present in the metabolic cascade
generate a range of inositol phosphate derivatives such as IP3 and
phosphatidylinositol [59]. They may be associated with the
homeostasis of calcium in the SMG tissue cells of BM Soup-
treated NOD mice.
Talin-1, actin and extracellular matrix protein FRAS1 precur-
sor were also down-regulated in BM Soup-treated mice. These
proteins are associated with the focal adhesion pathway. Focal
adhesions (FAs) are complex plasma membrane-associated mac-
romolecular assemblies that serve to physically connect the actin
cytoskeleton to integrins that engage with surrounding extracel-
lular matrix (ECM) [60]. FA-related signaling networks dynam-
ically modulate the strength of the linkage between integrin and
actin and control the organization of the actin cytoskeleton [60].
In a previous study, the expression of FA proteins was found to be
lower in adult salivary acinar population when compared with
embryonic glandular tissue [61]. In SS, focal adhesions may be
constantly assembled as the motile lymphocytes establish new
contacts at the leading edge following cellular signals to damaged
biological tissue. Our study seems to suggest that BM Soup
treatment inhibits the FAs in the SMGs of the NOD mice.
Lastly but importantly, BM Soup treatment also altered the
expression of growth factors and cytokines in the SMGs of NOD
mice. Due to their low abundance, these molecules are not readily
detected with the MS-based proteomic approach. As shown in
Fig. 4, qRT-PCR analysis indicated that epidermal growth factor
(EGF), nerve growth factor (NGF), and BMP7 (bone morphoge-
netic protein 7) were up-regulated whereas tumor necrosis factor
alpha (TNFa) was down-regulated in the SMGs of the NOD mice
treated by BM Soup. The reduced expression of TNFa suggests
that BM Soup treatment inhibited the inflammation in the SMGs
of the NOD mice. However, the over-expression of growth factors
EGF, NGF and BMP7 implies that BM Soup treatment may
repair the damaged SGs in NOD mice through the regulation of
these growth factors involved in SG development/maintenance. In
fact, direct injections or vector-mediated transfer of growth factors
(such as FGF2, IGF, KGF or VEGF) without cell transplants have
been reported partially effective in repairing irradiated SGs in
mice [22].
Taken together, these results suggest that BM Soup (cell extract)
is a novel and promising strategy to SS treatment because animal
model studies have shown that transplants with BM Soup can
functionally restore the damaged salivary glands in SS mouse
models. Through the analysis of protein/gene alterations in the
SMG tissues of the BM Soup-treated NOD mice, we have found
that BM Soup treatment might be effective due to inhibiting
apoptosis, focal adhesion and inflammation whereas promoting
the development, regeneration and differentiation of SG cells.
These findings provide important insights on the potential
mechanisms underlying the BM Soup treatment for functional
restoration of damaged SGs in NOD mice. However, there was
discrepancy between proteomics and qPCR analysis for a few
genes, which might result from a limited sample size in the studied
animal model groups. Although it is known that protein and
mRNA expression levels may not be well correlated, additional
studies are certainly warranted to further confirm the identified
target genes and their related signaling pathways that are
responsible for the BM Soup treatment.
Materials and Methods
Animals and BM Soup Preparation
All procedures with animal studies were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
McGill University (Approved protocol #5330, www.animalcare.
mcgill.ca). Seven week-old female NOD mice from Taconic Farms
(Germantown, NY) were housed untouched for a one-week
acclimatization period in the Genome Quebec Animal Facility
at McGill University. Then they were randomized into two
groups: a) BM Soup treatment (n = 6) and b) no treatment (n = 6)
Female NOD mice from the ‘‘BM Soup’’ group were injected via
the lateral tail vein using an approved restrainer and a 29G
syringe, twice weekly for 2 consecutive weeks, with the BM Soup
extracted from male donor MHC class I-matched bone marrow
cells harvested from aged-matched CByF1B6F1/J mice (Jackson
Laboratory, NY). Donor mice were sacrificed and then the
muscles were immediately removed and the bones were exposed.
Briefly BM Soup was obtained by flushing BMDCs from tibias and
femurs with cold PBS. The suspension was then strained through a
40-mm filter and washed again with PBS. Cell concentration was
adjusted to 107 cells/100 ml PBS. BM Soup was prepared as
described by Yeghiazarians et al [62], with modifications, by
subjecting BMDCs to three cycles of freeze-thaw on a container
with dry ice placed in a 280C freezer and thawing in a 37C bath,
followed by microcentrifugation at 13,500 g at 4C for 30 min to
remove insoluble materials. Protein concentration of BM Soup
was ,1.3 mg/ml (from 107 cells). Non-treated NOD mice (i.e. the
‘‘Control group’’, n = 6), were expected to develop diabetes during
the course of the follow-up period, and therefore any mouse with a
glucose level above 250 mg/dL received daily injections of insulin
to control their blood sugar levels.
At 20 weeks of age (i.e. 12 weeks after BM Soup therapy), blood
was taken from NOD mice using cardiac puncture method and
then the mice were sacrificed. The SMG glands were immediately
removed from the mice and frozen at 280uC. Due to gland
dissection and sample preparation issues, we only had high quality
RNA and protein samples from 5 treated NOD mouse glands and
4 untreated NOD mouse glands. For the comparative qPCR
analysis, we used an equal sample size of n = 4 per group.
Euthanasia of mice was performed using carbon dioxide
asphyxiation. In order to minimize stress, the mice were sacrificed
in their home cage (7.250611.50650) with a maximum of five adult
mice and no mice were pooled from different cages. The regulator
of carbon dioxide was set as 2 L/min for standard mouse cage
(7.250611.50650). Once the mice became unconscious, the flow
rate was increased to minimize the time of death and maintained
until the animals stopped breathing. Afterwards, the regulator was
closed and the mice were left in contact with carbon dioxide for an
additional 2 minutes. To confirm death, the mice was checked for
the following signs: no rising and falling of chest, no palpable heart
beat, poor mucous membrane color, no response to toe pinch,
color change or opacity in eyes.
Measurements of Salivary Function
Salivary flow rate (SFR) was obtained by using inhalation
anesthetic. Anesthesia was accomplished using 5% Isoflurane, 5%
Halothane, and 0.5–1 L/min oxygen for induction and 1%
Isoflurane, 1% Halothane and 0.5 L/min Oxygen for mainte-
Bone Marrow Cell Treatment for Sjogren’s Disease
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e87158
nance. 0.5% L/min Oxygen was used during the recovery period.
Whole saliva was collected after stimulation of secretion using
0.5 mg pilocarpine/kg body weight administered subcutaneously.
Saliva was obtained from the oral cavity by micropipette, placed
into pre-weighed 0.5-ml microcentrifuge tubes. Saliva was
collected for a 10-minute period and its volume determined
gravimetrically. SFR was determined at week 10, week 16, and
week 20 of age. Linear Mixed Models and ANOVA analysis
(Tukey’s Post Hoc test) were used to determine statistical
differences (P,0.05) between the mouse groups. Mice between
and within the groups were compared at different time points
using the SPSS version 17 (IBM, USA).
Salivary Tissue Analysis
Focus score was performed as previously described [18]. Half of
a submandibular gland per mouse was fixed in 10% formalin and
embedded in paraffin. Sections were cut at 5–8 mm thick and
subsequently stained with hematoxylin and eosin (H&E). A score
of 1 is a foci (aggregate) of at least 50 inflammatory cells per 4 mm2
of salivary tissue.
Tandem Mass Tagging
The SMG tissues of NOD mice were lysed in 8 M urea with a
homogenizer. Then, the samples were centrifuged at 15,000 rpm
for 5 minutes at 4uC, the supernatants were removed and the
levels of proteins were quantified by the Bradford method.
Afterwards, the lysed samples were labeled with TMT Mass
Tagging Kit (TMT 6plex, Thermo Scientific). In brief, the SMG
tissue samples were precipitated overnight at 220uC with cold
ethanol. Following centrifugation at 4uC, speed 13500 RPM for
15 minutes. After removing amine-based buffers and thiol
reagents, samples were reduced, alkylated and digested overnight.
The control tissue sample was labeled with reagent 130 whereas
the BM Soup-treated sample was labeled with reagent 131.
Afterwards, we combined the labeled samples and performed the
strong-cation exchange using the VIVAPURE S mini H filter
(Sartorius stedim Biotech). The filter was pre-wet with sodium
acetate (25 mM) and centrifuged 20006g for 10 minutes. The
combined samples were added to the filter and centrifuged
20006g for 10 minutes at room temperature. The first filtrated
sample was collected and eight subsequent step elution (2.5 mM,
5 mM, 10 mM, 20 mM, 50 mM, 100 mM, 250 mM and 1 M)
were performed and fractions were vacuum dried. The dried
samples were resuspended with 0.1% formic acid prior to LC-
MS/MS.
2-D LC with MS/MS
Fractionated peptide samples were loaded on an Agilent
nanotrap column (Santa Clara, CA) and washed for 10 minutes
at 6 ml/min. Chromatography was performed using Eksigent 2D-
LC nanoflow system operating at 400 nl/min and a 90 minute
gradient. Separation was performed on a Microm 10060.1 mm
C18AQ column (200A, 3 um) using solvent A (0.1% Formic Acid)
and solvent B (99.9% ACN, 0.1% formic Acid) over 90 minute
gradient: (0–30% B (60 min), 35–80% B (10 min), 80% B (5 min),
and then the column was re-equilibrated). Data Dependent LC-
MS-MS was performed using an Orbitrap LTQ XL mass
spectrometer (Thermo Fisher, San Jose, CA) with the MS scan
performed in the Orbitrap analyzer using 2 microscans of
maximum time 50 ms and an automatic gain control of 1E5.
The top 3 ions of intensity greater than 5000 (excluding single
charge states) were selected for MS-MS. In each cycle, a MS-MS
fragmentation was generated using subsequent CID (collision
energy 35) and HCD (collision energy 42) scans performed in the
LTQ Iontrap and Orbitrap cell, respectively, which were then
combined in data processing to obtain quantitative and qualitative
data.
Bioinformatics Analysis
Database searching of tandem MS data was performed using
the Proteome Discoverer 1.2 (Thermo Fisher Scientific) and a
workflow created by the purpose of analysis of the raw data
obtained from LC-MS/MS. In brief, the files obtain from mass
spectrometry were *.RAW file and all data were loaded into the
Spectrum Files. The parameters for Spectrum Selector were set as
default. Next, the Reporter Ions Quantifier was set for TMT 6plex
(using 130 and 131). The data searching parameters were set as
the static modifications were N-terminus TMT6plex
(+229.163 Da), peptide-C terminus none and Carbamidomethyl
(Rev1/+57 Da). Proteins with high confidence were selected
according to standard identification criteria.
Gene Ontology and functional pathway analysis were per-
formed with the online informatics analysis tool - Data for
Annotation, Visualization and Integrated Discovery (DAVID).
International Proteome Index (IPI) accession numbers for
quantified proteins were converted into UniGene IDs and then
uploaded onto the DAVID for analysis.
Quantitative Real-Time PCR (qRT-PCR)
Gene expression analyses were performed using an Applied
BioSystems quantitative Real Time PCR (qRT-PCR) system
(model 7500). Salivary tissues were preserved in RNAlater solution
(Qiagen, Germantown, MD, USA). The extracted RNA integrity
number (RIN) was verified to be over 6 with an Angilent
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA).
The first-strand cDNA synthesis was performed by using Thermo-
script RT-PCR system (Invitrogen). qRT-PCR was done using
1 mg RNA per sample and TaqMan Universal Master Mix
(Applied Biosystems). The probes and primers sequences were:
Tumor necrosis factor alpha (TNF-a; Assay ID: Mm00443258),
Epidermal Growth Factor (EGF; assay ID: Mm 00438696),
Transforming Growth Factor-b (TGF-b; assay ID: Mm01178820),
Vascular Endothelial Growth Factor (VEGF; assay ID
Mm01281449), Aquaporin 5 (AQP5; Assay ID: Mm 437578),
insulin like growth factor receptor 1 (IGF-IR; Assay ID:
Mm00802841), Bone Morphogenetic Protein 7 (BMP7; assay
ID: Mm00432102), Nerve Growth Factor (NGF; assay ID:
Mm00443039). Glyceralhyde-3-phophate dehydrogenase
(GAPDH; Mm99999915-g1) and beta-actin (ACTB,
Mm00607939-s1) were used as endogenous reference genes. The
primers for the rest of genes including vimentin (VIM), parotid
secretory protein (PSP), alpha amylase (AMY), aquaporin 1
(AQP1), lacrimal androgen-binding protein (LABP), Sjogren’s
syndrome antigen B (SSB), and caspase 8 associated protein 2
(CASP8AP2), are shown in Table S2. The experiments were run
at 50uC for 2 min, 95uC for 10 min, and then for 40 cycles at
95uC for 15 s, and 60uC for 1 min.
As for qPCR data analysis, the expression levels of genes in
treated NOD mouse samples were plotted in relative to the
expression levels of genes in untreated NOD mouse samples.
Statistical analysis was performed with the Mann–Whitney–
Wilcoxon test (a.k.a., Wilcoxon rank-sum test) in the MedCalc
statistical software (MedCalc Software, Belgium) and p,0.05 was
considered as statistically significant.
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